AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims:

1. (currently amended) An isolated mammal ~~human~~ protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 80% sequence homology or greater to SEQ ID NO: 4.

2. (canceled)

3. (currently amended) The protein of claim 1 comprising an amino acid sequence wherein said sequence ~~protein comprises~~ has 80% sequence homology or greater to SEQ ID No: 4 and has sequence homology equal to or greater than 80% to SEQ ID Nos: 2 or 3.

4. (previously presented) The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 2.

5. (previously presented) The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 3, wherein the amino acid residue in position 135 is Asn, Ser or Asp and the three amino acid residues in positions 148 to 150 are the tripeptide Glu-Leu-Ala or the tripeptide Thr-Trp-Pro.

6. (currently amended) The protein of claim ~~3~~ 1 which comprises the amino acid sequence of SEQ ID NO. 4.

7. (previously presented) A peptide capable of binding an N-terminal fragment of plasminogen and which has an amino acid sequence comprising at least 10 contiguous amino acid residues of SEQ ID NO. 2.

8-25. (canceled)

26. (withdrawn - currently amended) A screening method for identifying a compound capable of interacting with a protein according to any one of claims 1 or 3-7 ~~to 6~~.

27. (withdrawn - currently amended) A compound identified through the screening method of claim 26 ~~25~~.

28. (withdrawn - currently amended) A method for treating an angiogenesis-related disease or disorder comprising administering an effective amount of the proteins or peptides of any one of claims 1 or 3-7 ~~3-8~~ to a patient in need thereof.

29. (withdrawn - currently amended) A method for manufacturing a composition for the treatment of an angiogenesis-related disease comprising mixing the peptides according to any one of claims 1 or 3-7 ~~3-8~~ with a suitable pharmaceutical carrier.

30. (previously presented) A composition comprising a protein or peptide according to any one of claims 1 or 3-7 together with a pharmaceutically acceptable carrier wherein said protein or said peptide does not cleave plasminogen kringle domains.

31. (previously presented) The protein of claim 3, wherein the amino acid sequence has approximately 90% sequence homology to SEQ ID Nos: 2, 3 or 4.

32. (previously presented) The protein of claim 3, wherein the amino acid sequence has approximately 95% sequence homology to SEQ ID Nos: 2, 3 or 4.

33. (previously presented) The protein of claim 3, wherein the amino acid sequence has approximately 98% sequence homology to SEQ ID Nos: 2, 3 or 4.

34. (canceled)

35. (previously presented) An isolated human protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 and wherein said protein comprises SEQ ID No: 4 and has sequence homology equal to or greater than 80% to SEQ ID Nos: 2 or 3.

36. (withdrawn - currently amended) A method for treating an angiogenesis-related disease or disorder comprising administering an effective amount of the proteins or peptides of claim ~~34 or~~ 35 to a patient in need thereof.

37. (withdrawn - currently amended) A method for manufacturing a composition for the treatment of an angiogenesis-related disease comprising mixing the peptides according to ~~any one of~~ claim~~s 34 or~~ 35 with a suitable pharmaceutical carrier.

38. (previously presented) A composition comprising a protein or peptide according to claim 35 together with a pharmaceutically acceptable carrier.